BioSpace News Archive

Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations, based on results of the KEYNOTE-189 trial.

Michael Fraser, CEO of the Association of State and Territorial Health Officials (ASTHO), issued the following statement today in response to a Michigan court’s decision to proceed with the prosecution of a sitting health official for decisions made in notifying the public about an outbreak of Legionnaires’ disease in Genesee County in 2014 and 2015:

Online-PhD-Degrees.com has recently released their list of the Best Online Schools for Doctoral Degrees in Occupational Therapy--a detailed index of the finest online schools with degrees in this discipline.

Anderson will oversee all company finance, accounting and M&A efforts as American Well rapidly expands in the US and global markets

Fitbit Charge 3 delivers a premium swimproof design, our most advanced health and fitness features, and is our smartest tracker yet – all with up to 7 days of battery lifei

PANTHERx® Specialty Pharmacy, The Rare Disease Specialty Pharmacy®, announces that it has been named to the 37th Annual Inc. 5000 list, recognizing the fastest-growing private companies in America. PANTHERx® is being recognized on this prestigious national list as the 49th fastest growing company overall and the 5th fastest growing company in Health.

The two California-based companies collaborate to offer Total Eye™ Serum delivered by PERK

Bio-Thera Solutions announced that the China National Drug Administration (CNDA) has accepted for review the Biologics License Application (BLA) for BAT1406

Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process

Capital Health is the first hospital in New Jersey, and among the first in the United States, to use the new EMBOTRAP II Revascularization Device since its recent approval from the US Food and Drug Administration (FDA) in July.